TY  - JOUR
PY  - 2022//
TI  - Ketamine use in pediatric depression: a systematic review
JO  - Psychiatry research
A1  - Meshkat, Shakila
A1  - Rosenblat, Joshua D.
A1  - Ho, Roger C.
A1  - Rhee, Taeho Greg
A1  - Cao, Bing
A1  - Ceban, Felicia
A1  - Danayan, Kevork
A1  - Chisamore, Noah
A1  - Vincenzo, Joshua D. Di
A1  - McIntyre, Roger S.
SP  - e114911
EP  - e114911
VL  - 317
IS  - 
N2  - Pediatric depression is a common psychiatric disorder that is associated with significant morbidity and mortality. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with demonstrated antidepressant effects in the adult population, however, the efficacy and safety of ketamine for the treatment of pediatric depression remains poorly understood. Electronic databases were searched from inception to June 2022 to identify relevant articles. Six articles involving 46 participants with a mean age of 15.7 years were included in this systematic review. Out of six articles, three were case reports, one was a randomized clinical trial (RCT) and two were open-label trials. All studies used 0.5 mg/kg intravenous ketamine except for one, which used 2-7 micrograms/kg. Ketamine was significantly associated with reduced depressive symptoms without severe adverse events. Taken together, the results of these studies demonstrated the potential role of ketamine for treating pediatric depression. Several important limitations were identified, most notably the small sample sizes of the component studies, and that all studies administered intravenous ketamine. Further studies with larger sample sizes and different administration modalities are needed to better determine the efficacy and safety of ketamine in pediatric depression.<p />  <p>Language: en</p>
LA  - en
SN  - 0165-1781
UR  - http://dx.doi.org/10.1016/j.psychres.2022.114911
ID  - ref1
ER  -